🚀 VC round data is live in beta, check it out!
- Public Comps
- Aurisco Pharmaceutical
Aurisco Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aurisco Pharmaceutical and similar public comparables like AbCellera, Sino Biological, Fortrea, Jubilant Pharmova and more.
Aurisco Pharmaceutical Overview
About Aurisco Pharmaceutical
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
Founded
1998
HQ

Employees
N/A
Website
Financials (LTM)
EV
$1B
Valuation Multiples
Start free trialAurisco Pharmaceutical Financials
Aurisco Pharmaceutical reported last 12-month revenue of $261M and EBITDA of $105M.
In the same LTM period, Aurisco Pharmaceutical generated $153M in gross profit, $105M in EBITDA, and $67M in net income.
Revenue (LTM)
Aurisco Pharmaceutical P&L
In the most recent fiscal year, Aurisco Pharmaceutical reported revenue of $249M and EBITDA of $99M.
Aurisco Pharmaceutical is profitable as of last fiscal year, with gross margin of 60%, EBITDA margin of 40%, and net margin of 26%.
Financial data powered by Morningstar, Inc.
Aurisco Pharmaceutical Stock Performance
Aurisco Pharmaceutical has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Aurisco Pharmaceutical's stock price is $3.31.
Aurisco Pharmaceutical share price increased by 0.1% in the last 30 days, and by 8.3% in the last year.
Aurisco Pharmaceutical has an EPS (earnings per share) of $0.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.1% | 0.1% | -15.0% | 8.3% | $0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAurisco Pharmaceutical Valuation Multiples
Aurisco Pharmaceutical trades at 5.2x EV/Revenue multiple, and 12.9x EV/EBITDA.
EV / Revenue (LTM)
Aurisco Pharmaceutical Financial Valuation Multiples
As of May 2, 2026, Aurisco Pharmaceutical has market cap of $1B and EV of $1B.
Aurisco Pharmaceutical has a P/E ratio of 20.0x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aurisco Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Aurisco Pharmaceutical Margins & Growth Rates
Aurisco Pharmaceutical grew revenue by 15% and EBITDA by 19% in the last fiscal year.
In the most recent fiscal year, Aurisco Pharmaceutical reported gross margin of 60%, EBITDA margin of 40%, and net margin of 26%.
Aurisco Pharmaceutical Margins
Aurisco Pharmaceutical Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Aurisco Pharmaceutical Operational KPIs
Aurisco Pharmaceutical's Rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aurisco Pharmaceutical's Rule of X is 79% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Aurisco Pharmaceutical Competitors
Aurisco Pharmaceutical competitors include AbCellera, Sino Biological, Fortrea, Jubilant Pharmova, ACROBiosystems, Evotec, PolyPeptide, Bora Pharmaceuticals, Oxford BioMedica and R&G PharmaStudies.
Most Aurisco Pharmaceutical public comparables operate across Contract Research & Manufacturing, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 12.8x | 16.0x | (5.5x) | (4.5x) | |||
| 7.8x | — | 20.0x | — | |||
| 0.8x | 0.8x | 11.0x | 10.8x | |||
| 2.1x | 2.0x | 10.7x | 13.3x | |||
| 7.4x | 6.8x | 26.0x | 24.0x | |||
| 1.2x | 1.2x | 22.1x | 24.0x | |||
| 3.7x | 3.4x | 32.5x | 25.3x | |||
| 3.4x | 3.2x | 9.5x | 9.2x | |||
This data is available for Pro users. Sign up to see all Aurisco Pharmaceutical competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aurisco Pharmaceutical
| When was Aurisco Pharmaceutical founded? | Aurisco Pharmaceutical was founded in 1998. |
| Where is Aurisco Pharmaceutical headquartered? | Aurisco Pharmaceutical is headquartered in China. |
| Is Aurisco Pharmaceutical publicly listed? | Yes, Aurisco Pharmaceutical is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Aurisco Pharmaceutical? | Aurisco Pharmaceutical trades under 605116 ticker. |
| When did Aurisco Pharmaceutical go public? | Aurisco Pharmaceutical went public in 2020. |
| Who are competitors of Aurisco Pharmaceutical? | Aurisco Pharmaceutical main competitors include AbCellera, Sino Biological, Fortrea, Jubilant Pharmova, ACROBiosystems, Evotec, PolyPeptide, Bora Pharmaceuticals, Oxford BioMedica, R&G PharmaStudies. |
| What is the current market cap of Aurisco Pharmaceutical? | Aurisco Pharmaceutical's current market cap is $1B. |
| What is the current revenue of Aurisco Pharmaceutical? | Aurisco Pharmaceutical's last 12 months revenue is $261M. |
| What is the current revenue growth of Aurisco Pharmaceutical? | Aurisco Pharmaceutical revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Aurisco Pharmaceutical? | Current revenue multiple of Aurisco Pharmaceutical is 5.2x. |
| Is Aurisco Pharmaceutical profitable? | Yes, Aurisco Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aurisco Pharmaceutical? | Aurisco Pharmaceutical's last 12 months EBITDA is $105M. |
| What is Aurisco Pharmaceutical's EBITDA margin? | Aurisco Pharmaceutical's last 12 months EBITDA margin is 40%. |
| What is the current EV/EBITDA multiple of Aurisco Pharmaceutical? | Current EBITDA multiple of Aurisco Pharmaceutical is 12.9x. |
| How many companies Aurisco Pharmaceutical has acquired to date? | Aurisco Pharmaceutical hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Aurisco Pharmaceutical has invested to date? | Aurisco Pharmaceutical hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Aurisco Pharmaceutical
Lists including Aurisco Pharmaceutical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.